Next-Gen Expression Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Next-Gen Expression Systems
More sophisticated biological expression systems expand the functionality of the traditional systems for protein synthesis.


Pharmaceutical Technology
Volume 35, Issue 6, pp. 36-39

Expression systems for biobetters

Several groups have been working on ways to develop protein therapeutics in the same way that small-molecule therapeutics are developed. That is, they introduce systematic changes to the molecule, and assay how the changes affect properties, such as metabolic stability, affinity, and efficacy. However, protein biochemistry is not as flexible as small-molecule chemistry. The biological activity of a protein depends on correct three-dimensional structure, and small changes in protein stereochemistry may dramatically affect protein stability, affinity for its receptor, or efficacy. Moreover, the amino acids that make up mammalian proteins have a limited capacity for chemical modification. Reactive side groups are found on lysine and on cysteine, but there is no way to target a single amino acid for modification. Any modification targeted, for instance, to lysine, would potentially affect all the lysines in the protein, but would be more likely to produce proteins with a heterogeneous mixture of modified and unmodified sites.

The ability of protein chemists to modify the naturally occurring form of a protein has been advanced by Ambrx of San Diego. They have developed manufacturing-scale expression systems that allow insertion of nonnatural amino acids into defined positions in the protein, says Dr. Ho Cho, chief technology officer at Ambrx. The purpose of doing so is two-fold. First it allows one to introduce targeted changes to the protein, and to determine how these changes affect protein structure and function. Second, it allows manufacturers to use the nonnatural amino acid as a site that can be selectively chemically modified. The technology was originally developed in E. coli, and marketed as the ReCode expression system, which stands for Reconstituting Chemically Orthogonal Directed Engineering. It has since been expanded to eukaryotic cells, (e.g., yeast and CHO cells), and is marketed as the EuCode expression system. The EuCode expression systems are capable of producing fully glycosylated, multi-subunit proteins, such as antibodies and blood factors, that incorporate nonnatural amino acids, says Cho.

In the EuCode system, cells contain an orthogonal transfer RNA (O-tRNA) that will read through (suppress) a stop codon called amber. Ambrx has engineered tRNA synthtases that will amino acylate the O-tRNA with an Ambrx nonnatural amino acid. When the ribosomal complex encounters the amber stop codon, the amino acylated O-tRNA will insert the nonnatural amino into the elongating protein. The O-tRNA and tRNA sythetases are orthogonal, because they do not interfere with the cells' endogenous tRNAs, tRNA synthetases, or the incorporation of naturally occurring amino acids into the protein. In the absence of an Ambryx amino acid, protein synthesis is terminated at the amber codon.

The expression system is currently used to introduce a single amino acid substitution at a specific site to minimize disturbance to the rest of the protein, to preserve the protein's normal structure and function. Orthogonal tRNA synthetases have been developed for >50 nonnatural amino acids that possess unique functional properties. The nonnatural-amino-acid substitution can be used to explore structure-function relationships in fully glycosylated proteins, or as sites of attachment for effector molecules to enhance protein function, as in the case of drug-antibody conjugates or improve metabolic stability. The ReCODE system has been successfully scaled to >50,000 L fermentation with consistant product titers of >5 g/L.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here